PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
11.19
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.57. Joel Greenblatt would see extra liquidity as a cushion for downturns.
11.19
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 1.96. Joel Greenblatt would see a superior short-term safety net.
0.71
Cash Ratio near Drug Manufacturers - Specialty & Generic median of 0.77. Charlie Munger would see it as typical for the sector’s operating style.
-20.97
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.